120 related articles for article (PubMed ID: 20589638)
1. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
Meazza C; Casanova M; Luksch R; Podda M; Favini F; Cefalo G; Massimino M; Ferrari A
Pediatr Blood Cancer; 2010 Oct; 55(4):617-20. PubMed ID: 20589638
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
6. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
Tursz T
Semin Oncol; 1996 Jun; 23(3 Suppl 7):34-9. PubMed ID: 8711500
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
10. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
11. Dana-Farber Cancer Institute studies in advanced sarcoma.
Antman KH; Elias A
Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
[TBL] [Abstract][Full Text] [Related]
12. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
[TBL] [Abstract][Full Text] [Related]
13. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J
Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
15. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
